Differential Glioma-Associated Tumor Antigen Expression Profiles of Human Glioma Cells Grown in Hypoxia

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Ge, Lisheng ^a   Cornforth, Andrew N ^b   Hoa, Neil T ^a   Delgado, Christina ^a   Chiou, Shiun Kwei ^a   Zhou, Yi Hong ^c,d   Jadus, Martin R ^a,c,e  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b California Stem Cell Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 3; PROTEIN AIM2; PROTEIN ART 4; PROTEIN EPHA2; PROTEIN FOSL1; PROTEIN PRECURSOR; PROTEIN PTH RP; PROTEIN TRP1; PROTEIN WHSC2; PROTEIN YKL 40; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR SOX11; TUMOR ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CELL HYPOXIA; CELL STRAIN; CELL STRAIN D54; CELL STRAIN U251; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; ELECTROPHORESIS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NEURAL STEM CELL; NONHUMAN; NUDE MOUSE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSIENT EXPRESSION; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANOXIA; ANTIGENS, CD; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CELL LINE, TUMOR; FLOW CYTOMETRY; GLIOMA; GLYCOPROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; OXYGEN; PEPTIDES; POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC;

MUS MUSCULUS;

EID: 84866012865     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042661     Document Type: Article

References (56)

1. Finch CA, Lenfant C, (1972) Oxygen Transport in Man. N Engl J Med 286: 407-415.
2. Höckel M, Vaupel P, (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276.
3. Bertout JA, Patel SA, Simon MC, (2008) The impact of O2 availability on human cancer. Nature Reviews Cancer 8: 967-975.
4. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D, (2002) Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7: 492-508.
5. Collingridge DR, Piepmeier JM, Rockwell S, Knisely JPS, (1999) Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiothera and Oncol 53: 127-131.
6. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, et al. (2004) Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 10: 8177-8184.
7. Evans SM, Judy KD, Dunphy I, Jenkins WT, Nelson PT, et al. (2004) Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 64: 1886-1892.
8. Bar EE, (2011) Glioblastoma, cancer stem cells and hypoxia. Brain Pathology 21: 119-121.
9. Jensen RL, (2009) Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudo-progression, and as a therapeutic target. J of Neuro-Oncol 92: 317-335.
10. Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, et al. (2004) Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 64: 920-927.
11. Chi JT, Wang Z, Nuyten DSA, Rodriguez EH, Schaner ME, et al. (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3 (3) (): e47 doi:10.1371/journal.pmed.0030047.
12. Sathornsumetee S, Cao Y, Marcello JE, Herndon JEII, McLendon RE, et al. (2008) Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26: 271-278.
13. Chouaib S, Messai Y, Couve S, Escudier B, Hasmim M, et al. (2012) Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Frontiers in Immunology 3: 21.
14. Jackson C, Ruzevick J, Phallen J, Belcaid Z, Lim M, (2011) Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clinical and Developmental Immunology 2011: 732413.
15. Haque A, Banik NL, Ray SK, (2011) Molecular alterations in glioblastoma: potential targets for immunotherapy. Progress in Molecular Biology and Translational Science 98: 187-234.
16. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, (1997) KO (1997) Treatment of recurrent glioma with intracavity alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol. Immunother 45: 77-87.
17. Kruse CA, Rubinstein D (2001) "Cytotoxic T lymphocytes reactive to patient major histocompatibility proteins for therapy of recurrent primary brain tumors," Brain Tumor Immunotherapy, Liau, LM, Becker, DP, Cloughsey, TF, Bigner, D. editors. New York: Humana Press, pp. 149-170.
18. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, et al. (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T cell infiltration. Cancer Res 61: 842-847.
19. Yu JS, Liu G, Ying H, Yong WH, Black KL, et al. (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T cells in patients with malignant glioma. Cancer Res 64: 4973-4979.
20. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, et al. (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11: 5515-25.
21. Kim W, Liau LM, (2010) Dendritic cell vaccines for brain tumors. Neurosurg. Clinics of North America 21: 139-157.
22. Yamanaka R, Kajiwara K, (2012) Dendritic cell vaccines. Advances in Experimental Medicine and Biology 746: 187-200.
23. Hickey MJ, Malone CC, Erickson KL, Jadus MR, Prins RM, et al. (2010) Cellular and vaccine therapeutic approaches for gliomas. J of Translational Medicine 8: 100 Doi:10.1186/1479-5876-8-100.
24. Ge L, Hoa N, Bota DA, Natividad J, Howat A, et al. (2010) Immunotherapy of brain cancers: the past, the present and future directions. Clin and Develop Immunol 2010: 296453.
25. Grauer OM, Wesseling P, Adema GJ, (2009) Immunotherapy of diffuse gliomas: biological background, current status and future developments. Brain Pathol 19: 674-693.
26. Toda M, (2012) Glioma antigen. Advances in Experimental Medicine and Biology 746: 77-84.
27. Heimberger AB, Sampson JH, (2011) Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncology 13: 3-13.
28. Izumoto S, (2012) Peptide vaccine. Advances in Experimental Medicine and Biology 746: 166-177.
29. Parney IF, (2012) Basic concepts in glioma immunology. Advances in Experimental Medicine and Biology 746: 42-52.
30. Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, et al. (2012) Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 135: 1042-1054.
31. Jarboe JS, Johnson KR, Choi Y, Lonser RR, Park JK, (2007) Expression of Interleukin-13 receptor α2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res 67: 7983-7986.
32. Little SE, Popov S, Jury A, Bax DA, Doey L, et al. (2012) Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. Cancer Res 72: 1614-1620.
33. Zhang JG, Eguchi J, Kruse CA, Gomez G, Fakhrai H, et al. (2007) Antigenic profiling of glioma cells to generate antigenic vaccines or dendritic cell-based therapeutics. Clin Cancer Res 13: 566-575.
34. Zhang JG, Newcomb E, Zagzag D, Kruse CA, Driggers L, et al. (2008) Tumor antigen precursor protein profiles of adult and pediatric brain tumors identifies potential targets for immunotherapy. J Neuro-Oncol 88: 65-76.
35. Griguer CE, Oliva CR, Gillespie GY, (2005) Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines. J Neuro-Oncol 74: 123-133.
36. Griguer CE, Oliva CR, Kelley EE, Giles GI, Lancaster JR Jr, et al. (2006) Xanthine oxidase-dependent regulation of hypoxia-inducible factor in cancer cells. Cancer Res 66: 2257-2263.
37. Jiang BH, Semenza GL, Bauer C, Marti HH, (1996) Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 271 (Cell Physiol) (): C1172-1180.
38. Ito M, Shichijo S, Tsuda N, Ochi M, Harashima N, et al. (2001) Molecular basis of T cell-mediated recognition of pancreatic cancer cells. Cancer Res 61: 2038-2046.
39. Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, et al. (2005) Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 11: 5900-5911.
40. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, et al. (2011) Gene expression profile correlates with T-Cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17: 1603-1615.
41. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano, et al, (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173.
42. Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, et al. (2008) Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Medical Genomics 1: 52 doi:10.1186/1755-8794-1-52.
43. Yamaguchi Y, Takagi T, Wada T, Yano K, Furuya A, et al. (1999) WHSC2: NELF, a multi-subunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell 97: 41-51.
44. Narita T, Yamaguchi Y, Yano K, Sugimoto S, Chanarat S, et al. (2003) Human transcription elongation factor NELF: identification of novel subunits and reconstitution of the functionally active complex. Mol Cell Biol 23: 1863-1873.
45. Orzan F, Pellegatta S, Poliani L, Pisati F, Caldera V, et al. (2010) Enhancer of zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol and Applied Neurobiol 37: 381-394.
46. Suvà ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, et al. (2009) EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 69: 9211-9218.
47. Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, et al. (2005) YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 11: 2258-2264.
48. Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, et al. (2005) YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 11: 3326-3334.
49. Faibish M, Francescone RA, Bentley B, Yan W, Shao R, (2011) A YKL-40 neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Therapeutics 25 10: 742-751.
50. Li A, Walling J, Ahn S, Kotliarov Y, Su Q, et al. (2009) Unsupervised analysis of transcriptome profiles reveals six glioma subtypes. Cancer Res 69: 2091-2099.
51. Hoa N, Ge L, Kuznetsov Y, McPherson A, Cornforth AN, et al. (2010) Glioma cells display complex cell surface topographies that resist the actions of cytolytic effector lymphocytes. J Immunol 185: 4793-803.
52. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, et al. (2010) Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccination with a-Type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethyl-cellulose in patients with recurrent malignant glioma. J Clin Oncol 29: 330-336.
53. Niu Y, Terasaki Y, Komatsu N, Noguchi M, Shichijo S, et al. (2009) Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients. Cancer Science 100: 2167-2174.
54. Li J, Yin C, Okamoto H, Mushlin H, Balgley BM, et al. (2008) Identification of a novel proliferation-related protein, WHSC1 4a, in human gliomas. Neuro-Oncology 10: 45-51.
55. Orzan F, Pellegatta S, Poliani PL, Pisati F, Caldera V, et al. (2011) Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathology and Applied Neurobiology 37: 381-94.
56. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.